A Multi-center Prospective Study to Understand Drug-Induced Liver Injury in Mainland China

What this Trial Is About

This research aims to understand patients with drug-induced liver injury DILI in various hospitals across mainland China, including Western medicine, Chinese medicine, integrated hospitals, and specialist hospitals for conditions like tuberculosis. The study focuses on evaluating the clinical characteristics, progression, and influencing factors of DILI in real-world clinical practice. It also seeks to learn about suspected drugs causing DILI, rechallenging, and patterns of liver biochemical abnormalities. The study is a multi-center, prospective, non-interventional cohort study that observes patients without providing experimental treatment. It involves different cohorts receiving standard care or treatments such as compound glycyrrhizin tabletsinjection, isoglycyrrhizinate magnesium injection, diammonium glycyrrhizinate capsules, bicyclol, silibinin capsules, ursodeoxycholic acid capsules, and N-acetylcysteine. The study will assess compliance with DILI guidelines, histological features, and specific populations including elderly and children with liver disease backgrounds. Participants will be monitored over time to observe disease progression including outcomes like death, liver failure, chronic DILI, or recovery within six months. Researchers will collect clinical data, liver function tests, and other relevant information to evaluate the course of DILI and factors affecting outcomes. The study will continue until December 2030, focusing on real-world data without altering patient treatment plans.

A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）